slv213
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2021 (NCT04843787)
Timeline
Indications
Studied for
Mechanism of action
- Cathepsin LINHIBITOR
CTSL inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06146374 | Phase 1 | Nov 25, 2023 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT04843787 | Phase 2 | May 1, 2021 | FHI Clinical, Inc., Selva Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| FHI Clinical, Inc. | For profit | 1 | 0 | 1 | 2021 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2023 |
| Selva Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1